Join The Conversation Card Front 01 Copy

The Medtechy Daily: November 5

Posted on November 05, 2018 Share This Article:


The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.

Tweets of the Day

Headlines

Like Clockwork: How Daylight Saving Time Stumps Hospital Record Keeping. Modern technology has helped medical professionals do robot-assisted surgeries and sequence whole genomes, but hospital software still can’t handle daylight saving time. (Kaiser Health News)

Where Will Illumina, Inc. Be in 10 Years? There's no question about where Illumina, Inc. (NASDAQ:ILMN) stands today. The company is the undisputed leader in genomic sequencing. Illumina recently reported its highest sequencing instrument sales in years thanks to new products introduced in 2017 and 2018. (The Motley Fool)

The Internet of Medical Things Gold Rush (And My Grandfather's Wooden Leg). The most intriguing aspect of the recent Connected Health Conference was the eclectic mix of corporations claiming cutting-edge expertise in the Internet of Medical Things (IoMT). (Forbes)

Illumina Shows That Big Medtech Deals Are Far from Over. Just when it looked like the year would end without another mega-merger, Illumina has swooped in to acquire its rival, Pacific Biosciences (PacBio), for $1.2 billion. The move would solidify San Diego, CA-based Illumina’s position in the genetic sequencing market. The acquisition is expected to close in mid-2019. (MDDI)

Stryker, plaintiffs to settle hip implant cases. A Massachusetts federal judge last week stayed the multi-district litigation brought over hip implants made by Stryker (NYSE:SYK) so that the company and lawyers representing thousands of plaintiffs can hash out a settlement. (MassDevice)

Teleflex’s NeoTract wins Japanese approval for UroLift BPH treatment system. Teleflex (NYSE:TFX) subsidiary NeoTract said today it won Shonin approval from Japan’s Ministry of Health, Labor and Welfare for its Urolift system intended for treating benign prostatic hyperplasia. (MassDevice)

New Research Field Could Save Billions For Pharmaceutical Companies And Patients. This new methodology has been developed and implemented at the BiHELab and it has been evaluated and approved as a research product. (Forbes)